Articles related to PSYCHEDELICS

Recent phase 3 clinical trials have demonstrated the eye-opening potential of MDMA in the treatment of PTSD when paired with psychotherapy, providing a new method of patient care.

The preliminary findings suggest a potential new direction for managing chronic pain in PTSD, inviting further research and consideration in the clinical field.

AMA’s introduction of a CPT III code for psychedelic therapies denotes a potential paradigm shift in the treatment of mental health conditions, inviting clinicians to explore these emerging modalities.

Discover how the FDA’s first draft guidance on psychedelic drugs outlines a path for future medical treatments, addressing crucial considerations from study design to safety measures. Learn more about how this pivotal step could transform the therapeutic landscape.

This brief editorial introduces a series of articles describing the medical use of hallucinogens, ketamine, marijuana, and other agents — including the legal and ethical perspectives — in the treatment of various neurologic and psychiatric disorders.

This article provides a brief review of three important books on the thinking and experience around psychedelics in medicine: The Promise of Psychedelics, by Peter Silverstone, MD; Psychedelic Medicine, by Richard Louis Miller, MA, PhD; How to Change Your Mind, by Michael Pollan.